Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

NefIgArd Trial Investigators

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

147 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy'. En conjunto forman una huella única.

Medicine & Life Sciences